Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease

J Pediatric Infect Dis Soc. 2020 Feb 28;9(1):96-99. doi: 10.1093/jpids/piz033.

Abstract

Little information on the efficacy and pharmacokinetics of letermovir among immunocompromised children is currently available. We describe here the use of letermovir in a 2-year-old immunocompromised child with ganciclovir-resistant cytomegalovirus disease who required extracorporeal membrane oxygenation. Detailed information on therapeutic-drug-monitoring measures and dosage adjustments for letermovir is provided.

Keywords: cytomegalovirus disease; cytomegalovirus infection; letermovir; therapeutic drug monitoring.

Publication types

  • Case Reports

MeSH terms

  • Acetates / administration & dosage*
  • Acetates / pharmacokinetics
  • Acetates / therapeutic use
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / therapeutic use
  • Child, Preschool
  • Compassionate Use Trials
  • Cytomegalovirus Infections / drug therapy*
  • Cytomegalovirus Infections / immunology
  • Cytomegalovirus Infections / virology
  • Cytomegalovirus* / genetics
  • Cytomegalovirus* / isolation & purification
  • DNA, Viral / blood
  • Dose-Response Relationship, Drug
  • Drug Monitoring / methods*
  • Extracorporeal Membrane Oxygenation / adverse effects
  • Fatal Outcome
  • Female
  • Ganciclovir / therapeutic use
  • Hepatitis, Viral, Human / drug therapy
  • Hepatitis, Viral, Human / immunology
  • Humans
  • Immunocompromised Host*
  • Opportunistic Infections / drug therapy
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / virology
  • Polymerase Chain Reaction
  • Quinazolines / administration & dosage*
  • Quinazolines / pharmacokinetics
  • Quinazolines / therapeutic use
  • Treatment Failure
  • Viral Load

Substances

  • Acetates
  • Antiviral Agents
  • DNA, Viral
  • Quinazolines
  • letermovir
  • Ganciclovir